KADRİYE BAŞKURT

Dr. KADRİYE BAŞKURT

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
OAOrhun Akdoğan
Orhun Akdoğan
GUGalip Uyar
Galip Uyar
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
NMNuri Alperen Malkoc
Nuri Alperen Malkoc
OSOsman Sutcuoglu
Osman Sutcuoglu

12 January 2026 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
GUGalip Uyar
Galip Uyar
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
OAOrhun Akdoğan
Orhun Akdoğan
TTTuba Uğur Tuzcu
Tuba Uğur Tuzcu
OSOsman Sutcuoglu
Osman Sutcuoglu

9 May 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
GUGalip Uyar
Galip Uyar
OMOriol Mirallas
Oriol Mirallas
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
BMBerta Martin-Cullell
Berta Martin-Cullell
EYEnes Yeşilbaş
Enes Yeşilbaş
OSOsman Sutcuoglu
Osman Sutcuoglu
Accurate prediction of 90-day mortality in hospitalised cancer patients is critical for guiding personalised treatment decisions and optimising oncologic care. However, existing prognostic models often lack sufficient precision, particularly in distinguishing between high- and low-risk patients. In this retrospective study, we independently evaluated the prognostic performance of three scoring systems—the Prognostic Score for Hospitalised Cancer Patients (PROMISE), the Gustave Roussy Immune (GRIm) score, and the C-reactive protein–Triglyceride–Glucose Index (CTI)—in patients admitted for unplanned hospitalisations. This retrospective observational study was conducted at the Medical Oncology Clinic of Ankara Etlik City Hospital, Turkey, and included patients aged 18 years or older with a diagnosis of cancer who were hospitalised unexpectedly between February 2023 and February 2024. Laboratory data were retrieved from the institutional hospital information system. The PROMISE score was calculated using its original specification via the online tool (https://promise.vhio.net/). The GRIm score was calculated based on neutrophil-to-lymphocyte ratio (NLR), albumin, and lactate dehydrogenase (LDH). The CTI score was computed as: CTI = [0.412 × ln (C-reactive protein [CRP])] + ln [Triglyceride × Glucose/2], with a cut-off value of 4.78. A PROMISE–CTI Combined score was derived using regression-based weighting. Risk stratification was performed for all three scores using validated thresholds. Statistical analyses included Kaplan–Meier survival analysis, log-rank tests, univariable and multivariable logistic regression to assess predictors of 90-day mortality, and receiver operating characteristic (ROC) curve analysis to evaluate discriminatory performance. Among 1657 hospitalised cancer patients screened during the study period, 1109 met the inclusion criteria and were included in the analysis. PROMISE and GRIm scores were calculated for all 1109 patients, while CTI score was assessed in 333 patients with complete laboratory data. The 90-day mortality rate was 63.7% (n = 707). High PROMISE score (OR: 3.32, 95% CI: 1.40–7.86; p = 0.006) and high CTI score (OR: 2.85, 95% CI: 1.32–6.18; p = 0.008) were associated with increased 90-day mortality. Low PROMISE score (OR: 0.22, 95% CI: 0.10–0.49; p = 0.001) and low CTI score (OR: 0.35, 95% CI: 0.17–0.73; p = 0.003) were associated with reduced 90-day mortality. High GRIm score (OR: 1.83, 95% CI: 0.83–2.91; p = 0.07) and low GRIm score (OR: 0.73, 95% CI: 0.47–1.20; p = 0.08) were not significantly associated with 90-day mortality. The area under the curve (AUC) of the PROMISE–CTI Combined score was 0.884 (95% CI: 0.849–0.919; p < 0.0001). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the PROMISE–CTI Combined score were 92.4%, 81.1%, 85.3%, 89.6%, and 86.7%, respectively. The PROMISE score demonstrated strong discriminatory ability in predicting 90-day mortality among cancer patients admitted for unplanned hospitalisations. Integration of the CTI score further improved risk stratification by incorporating nutritional and inflammatory markers. The PROMISE–CTI Combined score may serve as a practical clinical tool for short-term prognostic assessment in this setting. Prospective, multicentre, randomised studies are needed to confirm the clinical utility and generalisability of the PROMISE–CTI Combined score. This study received no funding.


6 October 2025 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
SŞSemra Demirtaş Şenlik
Semra Demirtaş Şenlik
GUGalip Uyar
Galip Uyar
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
BOBerna Oksuzoglu
Berna Oksuzoglu
OSOsman Sutcuoglu
Osman Sutcuoglu

14 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
İOİlknur Deliktaş Onur
İlknur Deliktaş Onur
MDMutlu Dogan
Mutlu Dogan
MÖMehmet Akif Öztürk
Mehmet Akif Öztürk
TSTaha Koray Sahin
Taha Koray Sahin
MKMurat Kiracı
Murat Kiracı
ÖAöztürk Ateş
öztürk Ateş
Background: Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal tumors constitute 5% of metastatic colorectal cancer(mCRC). Immunotherapy is a new standard, but it is difficult to provide for all patients. 5-Flurouracil-based treatment with anti-EGFRs (cetuximab and panitumumab) in RAS/BRAF-wild or anti-VEGF (bevacizumab) is used in mCRC. Data is limited for the efficacy of anti-VEGF or anti-EGFRs in dMMR/MSI-H mCRC due to the small number of cases in the colorectal cancer population in trials. Aims: To evaluate prognostic factors in dMMR/MSI-H mCRC and compare progression-free survival time of patients receiving anti-VEGF and anti-EGFR combined with first-line 5FU-based therapy. Methods: Patients with metastatic dMMR/MSI-H colorectal cancer diagnosed between January 2015 and January 2023 were included in this cohort study. Progression-free survival times of patients treated with first-line therapy were compared. Prognostic factors associated with overall survival were investigated. Results: A total of 132 patients were included. Mutation rates were 35.6% (n:47) for RAS and 12.1% (n: 16) for BRAF (. Median progression-free survival (PFS) was 10.9 (95% CI: 9.2–12.6) months. Median overall survival (OS) was 44 months (95% CI: 26.23–63.03). 82 (62.1%) patients had primary tumor resection (PTR), 26 (19.7%) had PTR and metastasectomy. A total of 17 (12.8%) de novo mCRC patients had maximal cytoreductive surgery (MCS). A total of 14 (10.6%) patients had subsequent immunotherapy (IO). In multivariate analysis, RAS/BRAF mutation status, MCS, and subsequent IO are defined as prognostic factors for OS (p < 0.01, p: 0.022, and p: 0.005, respectively). No statistically significant difference (PFS, OS) was found in patients receiving first-line anti-VEGF or anti-EGFR therapy. Conclusions: dMMR/MSI-H mCRC is an entity with different tumor biology. We consider that dMMR/MSI-H mCRC patients with BRAF wild, MCS and subsequent IO have better outcomes with 1st line 5FU-based treatment with anti-VEGF/anti-EGFRs.